Prevalence: Brain metastases are a common complication of NSCLC, occurring in a significant percentage of patients with advanced-stage disease. The exact prevalence varies depending on the stage and subtype of NSCLC, but it can be seen in up to 40% of patients during the course of their illness.
Lung cancer is the leading cause of cancer mortality worldwide, accounting for 1.38 million annual deaths, representing 18.2% of total deaths from cancer 1).
Among those, approximately 7.4% of non-Small-cell lung cancer (NSCLC) patients will have brain metastases (BM) at presentation 2) Approximately 30% of patients with NSCLC develop brain metastases; about half of these patients have brain metastases at the time of diagnosis, while others develop brain metastases during periods of treatment 3) 4) 5) 6).